Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Effectiveness of Recombinant Human Serum Albumin Versus Human Serum Albumin in Patients With Hepatic Cirrhosis and Safety of Random, Double-blind, Parallel Grouping Phase II/III Clinical Trial

NCT05858853 is registered in ClinicalTrials.gov with Beijing Protgen Biotechnology Development Co., Ltd. as lead sponsor.

NCT NCT05858853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05858853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Effectiveness of Recombinant Human Serum Albumin Versus Human Serum Albumin in Patients With Hepatic Cirrhosis and Safety of Random, Double-blind, Parallel Grouping Phase II/III Clinical Trial
Lead sponsor
Beijing Protgen Biotechnology Development Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
May 24, 2023
Completion date
September 15, 2023
Enrollment
92 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhotic ascites